Secukinumab for Psoriasis

Phase-Based Progress Estimates
University of Miami, Miami, FLPsoriasis+1 MoreSecukinumab - Biological
18 - 65
All Sexes
What conditions do you have?

Study Summary

This trial will test whether a biologic drug can improve brain plasticity and perception of well-being for people with psoriasis.

Eligible Conditions
  • Psoriasis
  • Healthy Subjects

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

2 Primary · 7 Secondary · Reporting Duration: Baseline, Up to Week 4 (Visit 3)

Week 4
Change in PASI scores
Change in brain activity
Change in gray matter density
Change in itch score as measured by the NRS
Change in pain score as measured by the NRS
Change in participant well-being as measured by WHO-5
Change in physical activity as measured by 7D-PAR
Change in quality of sleep as measured by PSQI scores
Changes in stress in daily life as measured by PSQ

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Side Effects for

Secukinumab 300 mg
13%Upper respiratory tract infection
7%Back pain
4%Sinus congestion
4%Pharyngitis streptococcal
4%Postoperative wound infection
4%Muscle strain
4%Aphthous ulcer
4%Gastroenteritis viral
4%Urinary tract infection
2%Seborrhoeic dermatitis
2%Oropharyngeal pain
2%Otitis externa candida
2%Blood pressure increased
2%Productive cough
2%Decreased appetite
2%Squamous cell carcinoma
2%Ear discomfort
2%Ear pain
2%Nasal congestion
2%Actinic keratosis
2%Pruritus generalised
2%Tooth abscess
2%Ligament sprain
2%Suicidal ideation
2%Abdominal distension
2%Ligament rupture
2%Road traffic accident
2%Wound dehiscence
2%Peripheral swelling
2%Otitis media
2%Post procedural contusion
2%Muscle spasms
2%Lacrimation increased
2%Influenza like illness
2%Tinea pedis
This histogram enumerates side effects from a completed 2019 Phase 4 trial (NCT03055494) in the Secukinumab 300 mg ARM group. Side effects include: Nasopharyngitis with 19%, Upper respiratory tract infection with 13%, Back pain with 7%, Cough with 7%, Headache with 6%.

Trial Design

2 Treatment Groups

Healthy Group
1 of 2
Psoriasis Group
1 of 2

Active Control

Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: Secukinumab · No Placebo Group · Phase 4

Psoriasis Group
Experimental Group · 1 Intervention: Secukinumab · Intervention Types: Biological
Healthy GroupNoIntervention Group · 1 Intervention: Healthy Group · Intervention Types:
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, up to week 4 (visit 3)

Who is running the clinical trial?

University of MiamiLead Sponsor
804 Previous Clinical Trials
387,034 Total Patients Enrolled
NovartisIndustry Sponsor
1,588 Previous Clinical Trials
2,703,932 Total Patients Enrolled
8 Trials studying Psoriasis
4,018 Patients Enrolled for Psoriasis
Gil Yosipovitch, MDPrincipal Investigator - University of Miami
Larkin Community Hospital, Univ of Miami Hosp & Clinics-Sylvester Comp Cancer Center, University of Miami Hospital
Tel Aviv University (Medical School)
9 Previous Clinical Trials
229 Total Patients Enrolled
1 Trials studying Psoriasis
12 Patients Enrolled for Psoriasis

Eligibility Criteria

Age 18 - 65 · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
How old are they?
18 - 65100.0%
What site did they apply to?
University of Miami100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria50.0%
Met criteria50.0%
Why did patients apply to this trial?
  • "personal motivation and to help new effective treatments"
How many prior treatments have patients received?

Frequently Asked Questions

Does the research team accept younger individuals for this trial?

"This experiment necessitates that participants are aged between 18-65. Simultaneously, there are 86 trials available for minors and 537 clinical studies applicable to the elderly population." - Anonymous Online Contributor

Unverified Answer

Has Secukinumab gone through the necessary regulatory processes to be deemed safe for public consumption?

"Per our assessment, secukinumab is assessed to have a high degree of safety due it its Phase 4 trial status and concomitant approval for medical use." - Anonymous Online Contributor

Unverified Answer

Is there an opportunity for participants to join this research currently?

"Affirmative. suggest that this examination is actively enrolling participants as of now, with the trial having been first posted on June 29th 2021 and most recently updated around September 2022. To meet their goals, they need to recruit 40 patients from 1 medical centre." - Anonymous Online Contributor

Unverified Answer

What are the fundamental aims of this trial?

"This clinical trial seeks to assess the alteration of gray matter density within a Baseline, Up to Week 4 (Visit 3) timeline. Secondary objectives include evaluation of itch intensity using NRS ratings ranging from 0-10, sleep quality measured via PSQI scores between 0 and 49, as well as pain levels appraised with an identical numerical rating system." - Anonymous Online Contributor

Unverified Answer

Would I be eligible to partake in this clinical research?

"This clinical trial is enrolling 40 qualified participants aged 18 to 65 years old, who suffer from psoriasis. To be eligible for the study they must meet the following prerequisites: no contraindications to MRI scanning as verified by an MRI technologist using a site-approved screening form; a body surface area (BSA) of more than 5% affected by psoriasis and evidence of TB test in past 8 months or willingness to undertake one; absence of chronic pain, itch, skin conditions and any neurological/psychiatric diseases; women with child bearing potential will require pregnancy testing prior to enrolment; English fluency both" - Anonymous Online Contributor

Unverified Answer

Are there any analogous experiments involving Secukinumab?

"Currently, 27 clinical trials are being conducted to evaluate the efficacy of secukinumab. Among them, 13 have advanced into Phase 3. The primary sites for such research are Brest and Buenos Aires; however, over a thousand locations around the world are offering this therapy as part of their own experiments." - Anonymous Online Contributor

Unverified Answer

What circumstances is Secukinumab typically prescribed for?

"Secukinumab has been clinically tested to treat ankylosing spondylitis, [psoriatic arthritis](, and enthesitis related arthritis (ERA)." - Anonymous Online Contributor

Unverified Answer

What is the total enrollment of this experiment?

"Indeed, the data available on indicates that this medical trial is in a current search of participants. The first posting occurred on June 29th 2021 and has had its most recent update September 29th 2022. 40 patients need to be found over one site for recruitment purposes." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.